Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Inflammatory Bowel Diseases

  Free Subscription


16.10.2023

2 Aliment Pharmacol Ther
2 Am J Gastroenterol
1 BMC Gastroenterol
4 Clin Gastroenterol Hepatol
1 Dig Dis Sci
1 Eur J Gastroenterol Hepatol
3 Gastroenterol Hepatol
9 Inflamm Bowel Dis
2 J Crohns Colitis
1 J Gastroenterol
1 Lancet Gastroenterol Hepatol
1 Z Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. DAJTI E, Frazzoni L, Iascone V, Secco M, et al
    Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
    PubMed         Abstract available

  2. KAYAL M, Meringer H, Martin L, Colombel JF, et al
    Scores used to predict outcomes in acute severe ulcerative colitis: A systematic review.
    Aliment Pharmacol Ther. 2023 Oct 11. doi: 10.1111/apt.17731.
    PubMed         Abstract available


    Am J Gastroenterol

  3. GENERE JR, Ballard DH, Deepak P
    Three-Dimensional Modeling to Guide Interventional Endoscopy in Fibrostenotic Crohn's Disease.
    Am J Gastroenterol. 2023 Oct 13. doi: 10.14309/ajg.0000000000002558.
    PubMed        

  4. PHAM JT, Ghusn W, Acosta A, Loftus EV Jr, et al
    Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Oct 9. doi: 10.14309/ajg.0000000000002490.
    PubMed         Abstract available


    BMC Gastroenterol

  5. CHU X, Biao Y, Liu C, Zhang Y, et al
    Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis.
    BMC Gastroenterol. 2023;23:346.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  6. GEEM D, Hercules D, Pelia RS, Venkateswaran S, et al
    Progression of Pediatric Crohn's Disease is Associated with Anti-TNF Timing and BMI Z-Score Normalization.
    Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00757.
    PubMed         Abstract available

  7. A B, M N, B P, M F, et al
    Switching from intra-venous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post-hoc analysis of the REMSWITCH study.
    Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00766.
    PubMed        

  8. JANGI S, Hsia K, Zhao N, Kumamoto CA, et al
    Dynamics of the Gut Mycobiome in Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00762.
    PubMed         Abstract available

  9. DIGNASS A, Stremmel W, Horynski M, Poyda O, et al
    Modified-release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-blind, Randomized, Placebo-controlled Trials.
    Clin Gastroenterol Hepatol. 2023 Oct 6:S1542-3565(23)00771.
    PubMed         Abstract available


    Dig Dis Sci

  10. LAW CCY, Peraza J, Viera Feliciano N, Ungaro RC, et al
    Do We Need AI to Diagnose AI? Diagnosis and Management of Adrenal Insufficiency Following Steroid Therapy in a Patient with Inflammatory Bowel Disease.
    Dig Dis Sci. 2023 Oct 13. doi: 10.1007/s10620-023-08123.
    PubMed        


    Eur J Gastroenterol Hepatol

  11. BARAUNA FSB, Magro DO, Miranda EF, Marcal GN, et al
    Correlation between trough levels of infliximab and postoperative endoscopic recurrence in Crohn's disease patients submitted to ileocolonic resections.
    Eur J Gastroenterol Hepatol. 2023 Oct 6. doi: 10.1097/MEG.0000000000002639.
    PubMed         Abstract available


    Gastroenterol Hepatol

  12. IZQUIERDO VP, Frias-Ordonez JS, Cuadros C, Vargas M, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
    Gastroenterol Hepatol. 2023 Oct 9:S0210-5705(23)00442.
    PubMed         Abstract available

  13. PINERO G, Manosa M, Calafat M, Vayreda E, et al
    Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00439.
    PubMed         Abstract available

  14. IZQUIERDO VP, Frias-Ordonez JS, Banos FJ, Cuadros C, et al
    Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: a case series study.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00443.
    PubMed         Abstract available


    Inflamm Bowel Dis

  15. CUOMO M, Carobbio A, Aloi M, Alvisi P, et al
    Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response.
    Inflamm Bowel Dis. 2023;29:1380-1389.
    PubMed         Abstract available

  16. REIJNTJES M, de Jong D, Wessels E, Goetgebuer R, et al
    Crohn's Disease of the Ileoanal Pouch: A High Rate of Potential Overdiagnoses.
    Inflamm Bowel Dis. 2023 Oct 6:izad228. doi: 10.1093.
    PubMed         Abstract available


  17. Correction to: Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response.
    Inflamm Bowel Dis. 2023 Oct 9:izad239. doi: 10.1093.
    PubMed        

  18. KLEEBAYOON A, Wiwanitkit V
    SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Oct 10:izad230. doi: 10.1093.
    PubMed        

  19. O'SHEA D, Picoraro JA
    De Novo Crohn's Disease in the Pediatric Pouch.
    Inflamm Bowel Dis. 2023 Oct 10:izad231. doi: 10.1093.
    PubMed         Abstract available

  20. MARTINELLI M, Romeo E, Caldaro T, Dimakou K, et al
    De Novo Crohn's Disease in Children With Ulcerative Colitis Undergoing Ileal Pouch-Anal Anastomosis: A Multicenter, Retrospective Study From the Pediatric IBD Porto Group of the ESPGHAN.
    Inflamm Bowel Dis. 2023 Oct 10:izad199. doi: 10.1093.
    PubMed         Abstract available

  21. SMITH RA, Desai A, Hashash JG, Hayney MS, et al
    Addressing the Risks of Respiratory Syncytial Virus for Patients With Inflammatory Bowel Disease in the Era of Novel Vaccines.
    Inflamm Bowel Dis. 2023 Oct 10:izad233. doi: 10.1093.
    PubMed        

  22. TARIQ R, Loftus EV
    Home-based Biologic Infusions for Inflammatory Bowel Disease: Are We Ready for Prime Time?
    Inflamm Bowel Dis. 2023 Oct 11:izad240. doi: 10.1093.
    PubMed        

  23. SCHMOYER CJ, Sun K, Zack J, Kumar P, et al
    Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Inflamm Bowel Dis. 2023 Oct 11:izad226. doi: 10.1093.
    PubMed         Abstract available


    J Crohns Colitis

  24. RYMARCZYK D, Schultz W, Borowa A, Friedman JR, et al
    Deep learning models capture histological disease activity in Crohn's Disease and Ulcerative Colitis with high fidelity.
    J Crohns Colitis. 2023 Oct 10:jjad171. doi: 10.1093.
    PubMed         Abstract available

  25. VERSTOCKT B, Pivorunas V, Mahi NA, Smaoui N, et al
    Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.
    J Crohns Colitis. 2023 Oct 6:jjad170. doi: 10.1093.
    PubMed         Abstract available


    J Gastroenterol

  26. NAGANUMA M, Kobayashi T, Kunisaki R, Matsuoka K, et al
    Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02048.
    PubMed         Abstract available


    Lancet Gastroenterol Hepatol

  27. QUAN J, Markovinovic A, Hracs L, Ma C, et al
    Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Oct 6:S2468-1253(23)00310.
    PubMed        


    Z Gastroenterol

  28. MOLL-VON DER WETTERN M, Heinlein W, Rathmayer M, Koller L, et al
    [A critical DRG-evaluation of cases with inflammatory bowel disease].
    Z Gastroenterol. 2023 Oct 12. doi: 10.1055/a-2075-2533.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.